Literature DB >> 1886637

Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis.

A Lerman1, B S Edwards, J W Hallett, D M Heublein, S M Sandberg, J C Burnett.   

Abstract

BACKGROUND: Atherosclerosis is characterized by endothelial injury and the proliferation of arterial smooth-muscle cells. The latter may be a result of the release of growth factors from the vessel wall; such growth factors may include an endothelium-derived vasoconstrictor for peptide with mitogenic properties. We tested the hypothesis that plasma endothelin concentrations are elevated in persons with symptomatic atherosclerosis, independently of age.
METHODS: We measured plasma endothelin levels in 100 normal subjects and in 40 patients with atherosclerosis predominantly of the following types: aortic and peripheral vascular disease (14 patients), renovascular disease (9 patients) coronary artery disease (9 patients), and carotid disease (8 patients). We also performed immunohistochemical staining for endothelin in the walls of atherosclerotic vessels.
RESULTS: In the normal subjects, the mean (+/- SD) plasma endothelin concentration was 1.4 +/- 0.2 pmol per liter, with no correlation between age and plasma endothelin concentration (r = 0.13, P = 0.2). In the patients with symptomatic atherosclerosis, the mean plasma endothelin concentration was 3.2 +/- 1.2 pmol per liter (P less than 0.001), and there was a significant correlation between plasma endothelin and the number of sites of disease involvement (r = 0.89, P less than 0.001). In the immunohistochemical studies, endothelin-1-like immunoreactivity was observed in vascular smooth muscle as well as in endothelial cells.
CONCLUSIONS: Endothelin may be a marker for arterial vascular disease. Whether it participates in the atherogenic process or is merely released from damaged endothelial cells is unclear.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1886637     DOI: 10.1056/NEJM199110033251404

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  120 in total

1.  Achieving Optimal Reperfusion without Adjunctive Antithrombotic Therapy: Novel Thrombolytic Dosing Strategies.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

Review 2.  Bosentan and the endothelin system in congestive heart failure.

Authors:  S H Ellahham; V Charlon; Z Abassi; K A Calis; W K Choucair
Journal:  Clin Cardiol       Date:  2000-11       Impact factor: 2.882

3.  Plasma endothelin-1 levels in Behçet's disease.

Authors:  T Uslu; C Erem; M Tosun; O Deger
Journal:  Clin Rheumatol       Date:  1997-01       Impact factor: 2.980

Review 4.  Hemodynamic effects of bosentan in patients with chronic heart failure.

Authors:  W Kiowski; G Sütsch; E Oechslin; O Bertel
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

Review 5.  Endothelin A receptor antagonists in congestive heart failure: blocking the beast while leaving the beauty untouched?

Authors:  L E Spieker; G Noll; F T Ruschitzka; T F Lüscher
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

6.  Endothelin-1-induced endothelial microvesicles impair endothelial cell function.

Authors:  L Madden Brewster; Vinicius P Garcia; Ma'ayan V Levy; Kelly A Stockelman; Anabel Goulding; Noah M DeSouza; Jared J Greiner; Jamie G Hijmans; Christopher A DeSouza
Journal:  J Appl Physiol (1985)       Date:  2020-04-23

7.  Polyclonal 111In-IgG, 125I-LDL and 125I-endothelin-1 accumulation in experimental arterial wall injury.

Authors:  L Prat; G Torres; I Carrió; M Roca; V Riambau; L Berná; M Estorch; I Ferrer; C García
Journal:  Eur J Nucl Med       Date:  1993-12

8.  Plasma endothelin-1 concentrations in patients with retinal vein occlusions.

Authors:  A Iannaccone; C Letizia; S Pazzaglia; E M Vingolo; G Clemente; M R Pannarale
Journal:  Br J Ophthalmol       Date:  1998-05       Impact factor: 4.638

9.  Telomere length and replicative aging in human vascular tissues.

Authors:  E Chang; C B Harley
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

10.  Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice.

Authors:  M Barton; C C Haudenschild; L V d'Uscio; S Shaw; K Münter; T F Lüscher
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.